Opinion

Video

Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities

Author(s):

Catherine C. Coombs, MD,Matthew S. Davids, MD, MMSc

Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.

  1. Briefly comment on recent real world data regarding switching and sequencing to next line of therapy in patients with CLL. (Pinilla-Ibarz, et al. EHA 2024. Abstract P697)
  2. How do you interpret these data and how may they influence your overall treatment approach?
Related Videos
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
FDA
November 20th 2024

FDA Approves New Drug Labeling for Fludarabine Phosphate in CLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

First-Line Zanubrutinib in CLL/SLL
November 13th 2024

First-Line Zanubrutinib Prolongs PFS in Real-World Study of Chinese Patients With CLL/SLL

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Matthew Cortese, MD, MPH, assistant professor, oncology, Department of Medicine-Lymphoma, Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center
November 6th 2024

Obinutuzumab and Liso-Cel Revisions to CLL/SLL NCCN Guidelines Mark Most Notable Changes of 2024

HD-CAR-1 in Heavily Pretreated CLL | Image Credit: © Dr_Microbe - stock.adobe.com
November 4th 2024

HD-CAR-1 Treatment Is Safe and Feasible in Heavily Pretreated CLL